Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study.
Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study.
复制标题
DOI：
10.1186/1465-9921-8-57
复制
发表时间：
2007-08-05
影响因子：
5.8
通讯作者：
von Specht BU
中科院分区：
文献类型：
--
作者：
Baumann U;Göcke K;Gewecke B;Freihorst J;von Specht BU
针对铜绿假单胞菌的疫苗接种是预防囊性纤维化患者气道感染的理想策略，尽管具有挑战性。我们在I/II期临床试验中评估了基于下呼吸道铜绿假单胞菌外膜蛋白F和I的鼻疫苗的免疫原性。N = 12名健康志愿者接受了2次OprF-Opr I凝胶鼻疫苗接种，作为初次接种和全身接种（n = 6）或鼻加强接种（n = 6）。在诱导痰（IS）、支气管肺泡灌洗（BAL）和血清中评估抗体。在BAL和IS中发现OprF-OprI特异性IgG和伊加抗体的发生率相当，但主要同种型不同。IS中的伊加抗体与相应的血清水平不相关。所有接种者在接种后1年内均可检测到肺抗体。全身加强组血清IgG水平较高。然而，鼻腔助推器组有更好的长期反应与支气管抗体的两种同种型。鼻OprF-OprI疫苗在全身和气道粘膜部位均诱导持久的抗体应答。IS是一种可行的无创评估支气管抗体的方法。需要进一步优化疫苗接种计划。
Vaccination against Pseudomonas aeruginosa is a desirable albeit challenging strategy for prevention of airway infection in patients with cystic fibrosis. We assessed the immunogenicity of a nasal vaccine based on the outer membrane proteins F and I from Pseudomonas aeruginosa in the lower airways in a phase I/II clinical trial. N = 12 healthy volunteers received 2 nasal vaccinations with an OprF-OprI gel as a primary and a systemic (n = 6) or a nasal booster vaccination (n = 6). Antibodies were assessed in induced sputum (IS), bronchoalveolar lavage (BAL), and in serum. OprF-OprI-specific IgG and IgA antibodies were found in both BAL and IS at comparable rates, but differed in the predominant isotype. IgA antibodies in IS did not correlate to the respective serum levels. Pulmonary antibodies were detectable in all vaccinees even 1 year after the vaccination. The systemic booster group had higher IgG levels in serum. However, the nasal booster group had the better long-term response with bronchial antibodies of both isotypes. The nasal OprF-OprI-vaccine induces a lasting antibody response at both, systemic and airway mucosal site. IS is a feasible method to non-invasively assess bronchial antibodies. A further optimization of the vaccination schedule is warranted.
登录
查看更多内容
影响因子：
--
作者：
Göcke, K;Baumann, U;von Specht, BU
通讯作者：
von Specht, BU
影响因子：
3.6
作者：
Lang, AB;Rüdeberg, A;Schaad, UB
通讯作者：
Schaad, UB
影响因子：
10
作者：
Keatings, VM;Evans, DJ;Barnes, PJ
通讯作者：
Barnes, PJ
影响因子：
--
作者：
Mansouri, E;Blome-Eberwein, S;von Specht, BU
通讯作者：
von Specht, BU
影响因子：
24.3
作者：
Rutgers, SR;Timens, W;Postma, DS
通讯作者：
Postma, DS